PEP-Therapy Reports Positive Results From GLP-Toxicity Study of PEP-010 Drug Candidate

A major step towards clinical trials

PARIS–(BUSINESS WIRE)–PEP-Therapy, a biotechnology company developing peptides as targeted
therapies for oncology, announces that its first-in-class drug
candidate, PEP-010, successfully completed Good Laboratory Practice
(GLP) toxicity study, moving towards its first-in-human clinical trial.

PEP-010 was studied in rodent and non-rodent species, in a 4-week
toxicity study. The administration schedule was chosen to cover all
possible schedules that could be implemented during clinical trial. The
study was performed by a world leading CRO specialized in safety and
toxicology studies and in accordance with the OECD principles of Good
Laboratory Practice as accepted by regulatory authorities.

PEP-010 was well tolerated in rodent and non-rodent species. The study
confirmed the absence of systemic toxicity and neuro-behavioural
effects, and cardiovascular functions were unaffected by the treatment
at all the dose levels. Based on these results, the
no-observed-adverse-effect level (NOAEL) was defined and the starting
dose for the coming phase I clinical trial calculated.

« The PEP-Therapy team is very pleased with the outcome of this
study, which represents a key milestone for the company. The results are
very encouraging, PEP-010 is safe and well tolerated at doses
significantly higher than those intended to be studied in patients »
said Antoine Prestat, CEO and co-founder of PEP-Therapy. « We have
now gathered all required preclinical data paving the way for the
clinical study ».

Based on these positive results, the Phase I clinical batch and the
regulatory documents are in preparation for the submission of a Clinical
Trial Application in 2019. PEP-Therapy has entered into a collaborative
partnership for Phase I clinical trials with Institut Curie and Gustave
Roussy, two leading European cancer centres. The synopsis of the
clinical study protocol has been drawn-up for advanced solid tumours. Pr
Christophe Le Tourneau (Head of the Department of Drug Development and
Innovation (D3i) at Institut Curie) will be the Principal Investigator.
« We have been working with PEP-Therapy since the beginning of the
project, starting with preclinical work. We are now eager to start the
first-in-human clinical trial with a compound that successfully
completed GLP-toxicity studies. The Institut Curie is proud to sponsor
this clinical trial with such an innovative drug ».

About PEP-Therapy
PEP-Therapy is a medical biotechnology
company developing peptides as targeted therapies for oncology.
PEP-Therapy
has developed a Cell Penetrating and Interfering Peptide technology
(CP&IP) for the development of its therapeutic products. These
innovative molecules penetrate cells and then specifically block
relevant intracellular protein-protein interactions, thus inhibiting key
pathological mechanisms.
Founded in January 2014, PEP-Therapy is
building on research from Sorbonne University (formerly Pierre and Marie
Curie University, UPMC) and Institut Curie. Since its inception,
PEP-Therapy has raised 2,5 M€ from Quadrivium 1 seed fund, managed by
Seventure Partners, and from Dr Bernard Majoie, former Chairman and CEO
of Laboratoires Fournier, founding Chairman of Fournier-Majoie
Foundation for Innovation (FFMI).
For more details: www.pep-therapy.com

About PEP-010
PEP-010 is PEP-Therapy’s first CP&IP-based
product and a first-in-class targeted approach to cancer therapy.
PEP-010 specifically blocks the intracellular protein-protein
interaction between Caspase-9 and protein phosphatase 2A (PP2A), two
major effectors of the apoptosis pathway (programmed cell death).
PEP-010
has completed preclinical proof-of-concept demonstrating significant
anti-tumour activity in patient-derived xenograft (PDX) models. Repeated
GLP-toxicity studies showed a good tolerance of the product. Phase I
clinical regulatory documents are in preparation for submission of a
Clinical Trial Application shortly.

Contacts

Antoine Prestat, CEO – +33 1 53 10 05 48 – [email protected]